Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis: Application to Heart Failure with a Preserved Ejection Fraction


DOI: 10.1007/s12265-013-9472-1

Cite this article as:
Zile, M.R. & Baicu, C.F. J. of Cardiovasc. Trans. Res. (2013) 6: 501. doi:10.1007/s12265-013-9472-1


Comprehensive diagnostic criteria, accurate prognostic indicators, and effective treatment for patients with heart failure and a preserved ejection fraction (HFpEF) represent a critically important unmet need in cardiovascular medicine. Novel approaches to fill this unmet need are likely to be facilitated by targeting the underlying and unique pathophysiologic mechanisms that characterize patients with HFpEF. Two possible targets include hemodynamic overload evidenced by increased LV diastolic pressure (LVDP) and myocardial fibrosis evidenced by increased extracellular matrix fibrillar collagen. The measurement of LVDP and fibrosis generally requires either invasive procedures and/or complex and sophisticated imaging techniques. However, biomarkers measured in the plasma have been shown to accurately reflect changes in hemodynamic load and myocardial fibrosis and may have important application to the management of patients with HFpEF. The purpose of this review is to describe current and future applications of biomarkers in the management of patients with HFpEF.


Heart Failure Biomarkers Fibrosis 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Cardiology, Department of MedicineMedical University of South Carolina and Ralph H. JohnsonCharlestonUSA
  2. 2.Department of Veterans Affairs Medical CenterMedical University of South Carolina and Ralph H. JohnsonCharlestonUSA

Personalised recommendations